Press Releases

Press Releases

Date Title and Summary Additional Formats
Jun 13, 2018 Catalyst Pharmaceuticals Appoints Daniel J. Brennan as Chief Commercial Officer

CORAL GABLES, Fla. , June 13, 2018 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today

May 31, 2018 Catalyst Pharmaceuticals to Present at the Jefferies 2018 Global Healthcare Conference

CORAL GABLES, Fla. , May 31, 2018 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today

May 29, 2018 Catalyst Pharmaceuticals Announces FDA Acceptance of NDA and Priority Review Status for Firdapse® (Amifampridine Phosphate) for Lambert-Eaton Myasthenic Syndrome

--PDUFA Date Set for November 28, 2018 CORAL GABLES, Fla. , May 29, 2018 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular

May 09, 2018 Catalyst Pharmaceuticals Announces First Quarter 2018 Financial Results and Provides Corporate Update

--Company to Host Quarterly Conference Call at 8:30 am ET Tomorrow CORAL GABLES, Fla. , May 09, 2018 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating,

May 02, 2018 Catalyst Pharmaceuticals to Hold First Quarter Financial Results and Corporate Update Conference Call and Webcast on Thursday, May 10th, 2018

CORAL GABLES, Fla. , May 02, 2018 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today

Apr 24, 2018 Catalyst Pharmaceuticals Introduces New Corporate Website

CORAL GABLES, Fla. , April 24, 2018 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today is

Apr 19, 2018 Catalyst Pharmaceuticals Announces Enrollment of First Patient in Phase 3 Trial of Firdapse® in MuSK Antibody Positive Myasthenia Gravis

Pivotal Study sites in U.S. and Italy CORAL GABLES, Fla. , April 19, 2018 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular

Mar 29, 2018 Catalyst Pharmaceuticals Announces Submission of New Drug Application for Firdapse® for Treatment of Lambert-Eaton Myasthenic Syndrome
CORAL GABLES, Fla. , March 29, 2018 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced its
Mar 14, 2018 Catalyst Pharmaceuticals Announces Fourth Quarter and Year-End 2017 Financial Results and Provides Corporate Update
--Firdapse ® NDA to be Resubmitted Before the End of this Quarter --Significant Progress with MuSK-MG Regulatory and Clinical Program -- $84M Year-End Cash and Investments --Company to Host Quarterly Conference Call at 5:00 pm ET Today CORAL GABLES, Fla.
Mar 12, 2018 Catalyst Pharmaceuticals Announces Date and Time Change for Fourth Quarter and Year-End Financial Results Call and Webcast
CORAL GABLES, Fla. , March 12, 2018 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced that

Displaying 1 - 10 of 14